Oral diseases, including dental caries, periodontitis, and oral cancer, affect approximately 3.5 billion people worldwide, yet traditional antibiotic treatments are increasingly compromised by bacterial resistance. A new study published in Translational Dental Research provides a comprehensive review of antimicrobial peptides (AMPs) as a promising alternative, detailing their mechanisms, applications, and the hurdles to clinical adoption.
AMPs are small-molecule polypeptides that are key components of the innate immune system. Unlike conventional antibiotics that target specific metabolic pathways, AMPs primarily disrupt microbial cell membranes, a mechanism that reduces the likelihood of resistance development. Additionally, they exhibit immunomodulatory, anti-inflammatory, and tissue-regenerative properties, making them multifunctional agents in oral medicine.
The study, led by researchers in China and published in Translational Dental Research, reviews the roles of AMPs in major oral diseases. For dental caries, peptides such as Temporin-GHa derivatives, ZXR-2, and GH12 inhibit cariogenic bacteria like Streptococcus mutans, interfere with biofilm formation, and promote tooth remineralization. In periodontitis, human-derived AMPs (α-defensins, β-defensins) and synthetic peptides (e.g., Nal-P-113) kill periodontal pathogens, regulate inflammation, and enhance tissue regeneration. For oral cancer, AMPs like Piscidin-1 and LL-37 induce cancer cell death through membrane disruption and apoptosis while modulating anti-tumor immune responses. AMPs such as P-113 and Nisin A show efficacy against oral candidiasis, and peptides like IB-367 and Histatin-5 alleviate oral mucositis by inhibiting infection and promoting wound healing.
Several AMPs have entered clinical trials, including C16G2 for caries, Nal-P-113 for periodontitis, and P-113 for candidiasis. Beyond direct therapy, AMPs are being developed into implant coatings to prevent peri-implant infections, oral dressings for sustained release, and combined with antibiotics or nanoparticles for enhanced effects. They also hold promise as diagnostic markers by detecting expression level changes.
However, clinical translation faces challenges: oral enzymes, pH fluctuations, and high salt concentrations affect stability; cationic and amphiphilic properties can cause cytotoxicity and immunogenicity; and large-scale production is costly. To address these, researchers have developed strategies such as chemical modification (N-acetylation, lipidation), nanocarrier delivery systems, sequence optimization with D-amino acids, and microbial or plant-based heterologous expression. Senior co-corresponding author Qiang Feng notes, 'AMPs' multifunctional properties and low resistance potential make them a game-changer in oral medicine.'
The authors emphasize that future research should clarify AMP interactions with oral microbiota and host cells, accelerate peptide screening through artificial intelligence, and develop tailored formulations for the oral microenvironment to promote clinical application. The study was funded by grants from the National Natural Science Foundation of China and other sources, as detailed in the original press release.
